Professional Documents
Culture Documents
doi:10.1093/rheumatology/ken307
WORDS:
v54
The Author 2008. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For Permissions, please email: journals.permissions@oxfordjournals.org
Introduction
v55
Outcome
Comments
Renal biopsy
Dialysis requirement
Clinical outcome
Renal crisis frequency
C. P. Denton
v56
Acknowledgements
Outlook
Even today, the long-term mortality after SRC remains poor, especially if chronic dialysis is needed. This may reflect co-morbidity in a
subgroup of patients with active or extensive SSc but emphasizes
that this is an important complication. In the future, the main points
that need to be addressed in research are whether additional
vasoactive mediators may be targeted in a way that further improves
outcome, what the significance of renal impairment in SSc is and
whether treatments may prevent the development of SRC and so be
used prophylactically in high-risk cases [18].
References
1 Penn H, Howie AJ, Kingdon EJ et al. Scleroderma renal crisis: patient characteristics
and long-term outcomes. Q J Med 2007;100:48594.
2 Teixeira L, Mouthon L, Mahr A et al. Mortality and risk factors of scleroderma
renal crisis: a French retrospective study of 50 patients. Ann Rheum Dis
2008;67:1106.
3 Steen VD, Medsger TA. Changes in causes of death in systemic sclerosis,
19722002. Ann Rheum Dis 2007;66:9404.
4 Denton CP, Sweny P, Abdulla A, Black CM. Acute renal failure occurring in
scleroderma treated with cyclosporin A: a report of three cases. Br J Rheumatol
1994;33:902.
5 DeMarco PJ, Weisman MH, Seibold JR et al. Predictors and outcomes of
scleroderma renal crisis: the high-dose versus low-dose D-penicillamine in early
diffuse systemic sclerosis trial. Arthritis Rheum 2002;46:29839.
6 Steen VD, Medsger TA Jr. Case-control study of corticosteroids and other drugs that
either precipitate or protect from the development of scleroderma renal crisis.
Arthritis Rheum 1998;41:16139.
7 Della Bella S, Molteni M, Mascagni B, Zulian C, Compasso S, Scorza R. Cytokine
production in scleroderma patients: effects of therapy with either iloprost or
nifedipine. Clin Exp Rheumatol 1997;15:13541.
8 Scorza R, Rivolta R, Mascagni B et al. Effect of iloprost infusion on the resistance
index of renal vessels of patients with systemic sclerosis. J Rheumatol
1997;24:19448.
9 Gibney EM, Parikh CR, Jani A, Fischer MJ, Collier D, Wiseman AC. Kidney
transplantation for systemic sclerosis improves survival and may modulate disease
activity. Am J Transplant 2004;4:202731.
10 Kamen DL, Wigley FM, Brown AN. Antineutrophil cytoplasmic antibody-positive
crescentic glomerulonephritis in sclerodermaa different kind of renal crisis.
J Rheumatol 2006;33:18868.
11 Kingdon EJ, Knight CJ, Dustan K et al. Calculated glomerular filtration rate is a useful
screening tool to identify scleroderma patients with renal impairment. Rheumatology
2003;42:2633.
12 Denton CP, Bickerstaff MC, Shiwen X et al. Serial circulating adhesion molecule
levels reflect disease severity in systemic sclerosis. Br J Rheumatol
1995;34:104854.
13 Stratton RJ, Coghlan JG, Pearson JD et al. Different patterns of endothelial cell
activation in renal and pulmonary vascular disease in scleroderma. Q J Med
1998;91:5616.
14 Vancheeswaran R, Magoulas T, Efrat G et al. Circulating endothelin-1 levels in
systemic sclerosis subsetsa marker of fibrosis or vascular dysfunction?
J Rheumatol 1994;21:183844.
15 Kobayashi H, Nishimaki T, Kaise S et al. Immunohistological study endothelin-1 and
endothelin-A and B receptors in two patients with scleroderma renal crisis. Clin
Rheumatol 1999;18:4257.
16 Harvey GR, Butts S, Rands AL, Patel Y, McHugh NJ. Clinical and serological
associations with anti-RNA polymerase antibodies in systemic sclerosis. Clin Exp
Immunol 1999;117:395402.
17 Fonseca C, Renzoni E, Sestini P et al. Endothelin axis polymorphisms in patients
with scleroderma. Arthritis Rheum 2006;54:303442.
18 Wollheim FA. ACE inhibitors could prevent long-term damage in systemic
sclerosis patients experiencing scleroderma renal crisis. Clin Exp Rheumatol
2002;20:6134.